Quarterly report pursuant to Section 13 or 15(d)

WARRANTS

v3.24.1.1.u2
WARRANTS
3 Months Ended
Mar. 31, 2024
Warrants  
WARRANTS

Note 14. WARRANTS

 

The Company’s outstanding Common Stock warrants are equity classified. As of March 31, 2024, and December 31, 2023, the Company had 8,838,717 and 4,649,952 warrants outstanding to purchase one share of the Company’s Common Stock for each warrant at a weighted average exercise price of $3.53 and expire at various dates through March 2029. During the three months ended March 31, 2024, no warrants were exercised into an equivalent number of Common Shares as compared to 1,036,486 warrants being exercised during the three months ended March 31, 2023.

 

On March 8, 2024, the Company issued to certain investors (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock, with an exercise price of $1.64 (collectively, the “Transaction”), which Transaction constitutes a Dilutive Issuance under the terms of the Warrants. In addition, the placement agent was granted warrants to purchase 32,000 shares of Common Stock, with an exercise price of $1.64.

 

Section 3(b) of the Warrant Agreement executed during the IPO in September 2022 provides that in the event of a Dilutive Issuance, the Exercise Price of the Warrants shall be reduced and only reduced to equal the effective price per share of the Dilutive Issuance (the “Base Share Price”), and the number of Warrant Shares issuable thereunder shall be increased such that the aggregate Exercise Price payable pursuant to the Warrant, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment, provided that the Base Share Price shall not be less than $3.0625 (50% of the public offering price of the Units sold in the Company’s IPO) (subject to adjustment for reverse and forward stock splits, recapitalizations, and similar transactions).

 

The effect of the Transaction is such that the Exercise Price of the Warrants shall be reduced to $3.0625 per share. The new number of Warrant Shares is calculated by dividing (x) the number of Warrant Shares underlying the Warrant immediately prior to the Transaction multiplied by the Exercise Price in effect immediately prior to the Transaction, by (y) $3.0625. The calculations will be made to the nearest cent or the nearest 1/100th of a share.

 

As of March 8, 2024, and prior to the Transaction, there were Tradeable Warrants to purchase up to an aggregate of 1,601,259 shares of common stock outstanding and Non-Tradeable Warrants to purchase an aggregate of up to 2,704,554 shares of common stock outstanding.

 

    Number of
Warrants issued
    Weighted-average
exercise price
    Number of warrants exercised     Number of warrants outstanding  
Pre-IPO convertible notes     2,900,904     $ 5.31             2,900,904  
IPO tradeable     2,326,834       3.06       (725,576 )     1,601,259  
IPO non-tradable     3,015,464       3.06       (310,910 )     2,704,554  
Direct offering March 8, 2024     1,600,000       1.64             1,600,000  
Placement agent direct offering March 8, 2024     32,000       1.64             32,000  
Balance at March 31, 2024     9,875,202     $ 3.53       (1,036,486 )     8,838,717